Option Care Health (OPCH) Stock Overview
Offers home and alternate site infusion services in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
OPCH Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Option Care Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.67 |
| 52 Week High | US$36.80 |
| 52 Week Low | US$18.01 |
| Beta | 0.65 |
| 1 Month Change | -1.46% |
| 3 Month Change | -23.64% |
| 1 Year Change | -27.23% |
| 3 Year Change | -34.21% |
| 5 Year Change | 5.45% |
| Change since IPO | 95.58% |
Recent News & Updates
Seeking Alpha • Jul 05
Option Care Health: Mildly Interesting After Pullback
Summary Option Care Health shares have fallen 40% since January 2026, driven by Stelara's patent loss and insurance coverage switches impacting revenue and gross profit. Despite a $125M gross profit hit from Stelara, FY26 non-GAAP EPS and Adj. EBITDA guidance remains unchanged, supported by cost reductions and corporate actions. OPCH’s acute care portfolio outperformed, but market share losses and credibility concerns have pressured the stock, now trading at 15x FY26E EPS. With demographic tailwinds, a solid balance sheet, and insider buying, the recent selloff may offer a covered call entry point, though only for small, tactical positions. Read the full article on Seeking Alpha
Narrative Update • Jun 15
OPCH: Specialty Infusion Demand Will Offset Therapy Disruption Concerns Over Time
Analysts modestly reduced the fair value estimate for Option Care Health by about $0.60 to $28.58, as a wave of lower price targets and a new Neutral initiation highlighted ongoing therapy specific earnings uncertainty, alongside longer term growth tailwinds in specialty infusion. Analyst Commentary Recent Street research around Option Care Health has centered on how therapy specific disruption in its chronic portfolio collides with what analysts describe as durable growth tailwinds in specialty infusion.Recent updates
Seeking Alpha • Jul 05
Option Care Health: Mildly Interesting After Pullback
Summary Option Care Health shares have fallen 40% since January 2026, driven by Stelara's patent loss and insurance coverage switches impacting revenue and gross profit. Despite a $125M gross profit hit from Stelara, FY26 non-GAAP EPS and Adj. EBITDA guidance remains unchanged, supported by cost reductions and corporate actions. OPCH’s acute care portfolio outperformed, but market share losses and credibility concerns have pressured the stock, now trading at 15x FY26E EPS. With demographic tailwinds, a solid balance sheet, and insider buying, the recent selloff may offer a covered call entry point, though only for small, tactical positions. Read the full article on Seeking AlphaNarrative Update • Jun 15
OPCH: Specialty Infusion Demand Will Offset Therapy Disruption Concerns Over Time
Analysts modestly reduced the fair value estimate for Option Care Health by about $0.60 to $28.58, as a wave of lower price targets and a new Neutral initiation highlighted ongoing therapy specific earnings uncertainty, alongside longer term growth tailwinds in specialty infusion. Analyst Commentary Recent Street research around Option Care Health has centered on how therapy specific disruption in its chronic portfolio collides with what analysts describe as durable growth tailwinds in specialty infusion.Narrative Update • Jun 01
OPCH: Home And Alternate Site Care Demand Will Support Future Upside
The analyst price target for Option Care Health has been revised lower by about $1.55, as analysts factor in slightly higher discount rates, modestly softer revenue growth expectations, and a small adjustment to profit margin assumptions, while keeping future P/E broadly in line. Analyst Commentary Recent Street research on Option Care Health has been broadly focused on resetting price targets and ratings to reflect updated views on growth, margins, and risk, with several firms trimming their targets by mid to high single digit dollar amounts and some by double digits.
New Narrative • May 20
Home And Clinic Infusion Expansion Will Support Strong Long Term Earnings Potential
Catalysts About Option Care Health Option Care Health provides home and alternate site infusion therapy across acute, chronic and specialty treatments in the United States. What are the underlying business or industry changes driving this perspective?Narrative Update • May 03
OPCH: Home And Alternate Site Care Demand Will Support Long Term Upside
Analysts have trimmed their blended price target on Option Care Health by about $9 to roughly $31, as they factor in updated revenue growth assumptions, a slightly different profit outlook, and a lower future P/E multiple following a series of target cuts and a recent downgrade. Analyst Commentary Recent research updates on Option Care Health cluster around lower price targets and at least one downgrade.
New Narrative • May 02
Clinic Utilization And Payer Programs Will Shape Balanced Future For Infusion Services
Catalysts About Option Care Health Option Care Health provides home and alternate site infusion therapies across acute, chronic and specialty conditions in the United States. What are the underlying business or industry changes driving this perspective?Narrative Update • Apr 15
OPCH: Updated Revenue And Margin Assumptions Will Support Future Upside Potential
Analysts have raised their price targets on Option Care Health by $2 to $10, citing updated assumptions around revenue growth, profit margins and forward P/E. These revisions keep the estimated fair value steady near $40.09 per share.Narrative Update • Apr 01
OPCH: Expanded Buyback And Easing Drug Headwinds Will Support Future Returns
Analysts have nudged their price targets on Option Care Health higher, with recent moves up to $38 supported by views that Stelara related profit headwinds are becoming less significant and that key profitability and valuation assumptions remain broadly intact, with only slight adjustments to growth and margin expectations. Analyst Commentary Recent research has centered on how much Stelara related pressures still matter for Option Care Health and what that means for valuation.Narrative Update • Mar 17
OPCH: Expanded Buyback And Fading Drug Headwinds Will Support Future Returns
Analysts have nudged their price targets on Option Care Health higher, with recent moves such as $36 to $38 helping support a modest uplift in the updated analyst target range. This view is backed by expectations that near term Stelara related profit headwinds should ease further after 2026 and that valuation remains supported by slight adjustments in expected growth, margins, and future P/E levels.Narrative Update • Mar 03
OPCH: Buybacks And Easing Drug Headwinds Will Support Future Earnings
Narrative Update The analyst price target for Option Care Health is now framed around a fair value of about $40.09 per share, a small move from roughly $39.82. This is supported by several recent target increases from analysts who point to easing Stelara related profit headwinds and updated P/E assumptions, while revenue growth and discount rate inputs remain broadly similar.Narrative Update • Feb 17
OPCH: Buybacks And Waning Drug Headwinds Will Support Future Earnings Profile
Analysts have raised their average price target on Option Care Health by $10, citing updated assumptions on future P/E levels and an expectation that remaining Stelara related profit headwinds will ease after 2026. Analyst Commentary Recent research coverage has centered on how remaining Stelara related profit headwinds fit into the broader valuation story for Option Care Health, and what that could mean for execution expectations through 2026 and beyond.Narrative Update • Feb 03
OPCH: Buybacks And Easing Drug Headwinds Will Support Future Earnings Profile
Analysts have raised their price targets on Option Care Health, with fair value estimates moving from about $37.91 to $39.82, citing updated assumptions around the discount rate, revenue growth, profit margins, future P/E expectations, and the gradual easing of profit headwinds from Stelara over time. Analyst Commentary Recent price target moves cluster in a similar range, with bullish analysts citing updated assumptions around discount rates, revenue, profit margins, and future P/E expectations, as well as a view that Stelara related profit headwinds are gradually easing.Narrative Update • Jan 20
OPCH: Share Repurchases And Home Infusion Scale Will Offset Drug Profit Headwinds
Analysts lifted their price targets on Option Care Health by about $1.45 to roughly $37.91, pointing to easing Stelara related profit headwinds and the company's scale, therapeutic breadth, differentiated platform, and capital deployment plans as key supports for the updated outlook. Analyst Commentary Bullish Takeaways Bullish analysts highlight that Stelara and related biosimilars now account for under 1% of gross profit, which they see as limiting the impact of Stelara related profit headwinds on future earnings power.Analysis Article • Jan 07
Is Option Care Health (NASDAQ:OPCH) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Narrative Update • Jan 05
OPCH: Buybacks And Home Infusion Scale Will Drive Future Upside
Analysts have trimmed their price targets on Option Care Health to the mid US$30s, with one cut from US$38 to US$36. They cited solid recent revenue and gross profit, the company's leading position in home and alternative site infusion, and potential benefits from disciplined capital deployment including buybacks.Narrative Update • Dec 16
OPCH: Shares Will Reflect Buybacks And At-Home Care Demand Balancing Risks
Analysts have modestly raised their fair value estimate for Option Care Health to about $36.45 from $35.30 per share, reflecting confidence in the company's scale advantages, resilient growth profile, and prudent capital deployment despite a slightly lower consensus price target of $36. Analyst Commentary Street research on Option Care Health reflects a generally constructive view on the company’s competitive positioning and growth outlook, tempered by some reservations about valuation and near term catalysts for share appreciation.Narrative Update • Dec 02
OPCH: Shares Will Benefit From Buybacks And At-Home Care Demand
The consensus analyst price target for Option Care Health has been lowered from $38 to $36. Analysts express cautious optimism, noting strong recent results while highlighting limited immediate share catalysts and conservative future growth assumptions.Narrative Update • Nov 18
OPCH: Shares Appear Poised For Upside With Discounted Entry Point Ahead
Analysts have slightly reduced their price target for Option Care Health from $35.70 to $35.30. They cite expectations of modestly slower revenue growth and profit margins, though they remain positive on the company’s leading market position and capital allocation strategy.Narrative Update • Nov 01
OPCH: At-Home Infusion Demand Will Drive Shares Toward a 37% Upside
Option Care Health's fair value estimate has been revised downward from $37.90 to $35.70. Analysts cite strong operational performance, but note moderate near-term upside given the recent shift in industry multiples and a lack of immediate share catalysts.Narrative Update • Oct 03
Infusion Therapies And AI Will Transform Healthcare Delivery
Analysts have slightly lowered their average price target for Option Care Health to $37.90 from $38.78. This change reflects updated expectations for profit margins and revenue growth, while recognizing that the company's steady performance is already accounted for in current valuations.Analysis Article • Sep 09
Why Option Care Health, Inc. (NASDAQ:OPCH) Could Be Worth Watching
Option Care Health, Inc. ( NASDAQ:OPCH ), might not be a large cap stock, but it received a lot of attention from a...Analysis Article • Jul 25
An Intrinsic Calculation For Option Care Health, Inc. (NASDAQ:OPCH) Suggests It's 43% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Option Care Health fair value estimate is US$52.09 Current...Analysis Article • May 08
We Think The Compensation For Option Care Health, Inc.'s (NASDAQ:OPCH) CEO Looks About Right
Key Insights Option Care Health's Annual General Meeting to take place on 14th of May Total pay for CEO John Rademacher...Analysis Article • Apr 19
Option Care Health (NASDAQ:OPCH) Seems To Use Debt Quite Sensibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Mar 18
Why Investors Shouldn't Be Surprised By Option Care Health, Inc.'s (NASDAQ:OPCH) P/E
With a price-to-earnings (or "P/E") ratio of 26.4x Option Care Health, Inc. ( NASDAQ:OPCH ) may be sending very bearish...Analysis Article • Feb 19
Should You Investigate Option Care Health, Inc. (NASDAQ:OPCH) At US$32.09?
Option Care Health, Inc. ( NASDAQ:OPCH ), is not the largest company out there, but it led the NASDAQGS gainers with a...Analysis Article • Jan 23
Is There An Opportunity With Option Care Health, Inc.'s (NASDAQ:OPCH) 31% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Option Care Health fair value estimate is US$42.26 Option Care...Analysis Article • Dec 13
Option Care Health, Inc.'s (NASDAQ:OPCH) Business Is Trailing The Market But Its Shares Aren't
With a median price-to-earnings (or "P/E") ratio of close to 19x in the United States, you could be forgiven for...Analysis Article • Nov 28
Is Option Care Health (NASDAQ:OPCH) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Nov 02
Results: Option Care Health, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
As you might know, Option Care Health, Inc. ( NASDAQ:OPCH ) just kicked off its latest quarterly results with some very...Analysis Article • Oct 17
Should You Think About Buying Option Care Health, Inc. (NASDAQ:OPCH) Now?
Option Care Health, Inc. ( NASDAQ:OPCH ), might not be a large cap stock, but it saw a double-digit share price rise of...Analysis Article • Aug 30
There's Reason For Concern Over Option Care Health, Inc.'s (NASDAQ:OPCH) Price
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 18x, you may...
New Narrative • Aug 29
Orphan Therapies And Strategic Resilience Propel Company's Year-Over-Year Growth
Diversification into new therapies and engagement with the investment community signal growth and proactive market capture, enhancing future revenue.Seeking Alpha • Aug 16
Option Care Health: Revenue Lines Not Pulling Economic Weight (Rating Downgrade)
Summary Option Care has numerous revenue lines that are not pulling their economic weight, acting as a drag on performance. Returns on capital are tight, with management choosing to buy back stock vs. reinvesting in the business. In my view, compounding ability is low due to this fact, and valuations appear fully captured in the current range. Read the full article on Seeking AlphaAnalysis Article • Aug 15
We Think Option Care Health (NASDAQ:OPCH) Can Stay On Top Of Its Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Jul 15
What Does Option Care Health, Inc.'s (NASDAQ:OPCH) Share Price Indicate?
Option Care Health, Inc. ( NASDAQ:OPCH ), is not the largest company out there, but it saw significant share price...Shareholder Returns
| OPCH | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 1.5% | -1.9% | -1.4% |
| 1Y | -27.2% | 39.2% | 17.1% |
Return vs Industry: OPCH underperformed the US Healthcare industry which returned 39.2% over the past year.
Return vs Market: OPCH underperformed the US Market which returned 17.1% over the past year.
Price Volatility
| OPCH volatility | |
|---|---|
| OPCH Average Weekly Movement | 8.8% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: OPCH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: OPCH's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 7,397 | John Rademacher | optioncarehealth.com |
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapy and services; home infusion services to treat heart failure; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as Duchenne muscular dystrophy, multiple sclerosis, Alzheimer’s disease, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services.
Option Care Health, Inc. Fundamentals Summary
| OPCH fundamental statistics | |
|---|---|
| Market cap | US$3.42b |
| Earnings (TTM) | US$206.19m |
| Revenue (TTM) | US$5.67b |
16.5x
P/E Ratio0.6x
P/S RatioIs OPCH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OPCH income statement (TTM) | |
|---|---|
| Revenue | US$5.67b |
| Cost of Revenue | US$4.58b |
| Gross Profit | US$1.09b |
| Other Expenses | US$880.67m |
| Earnings | US$206.19m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 29, 2026
| Earnings per share (EPS) | 1.31 |
| Gross Margin | 19.18% |
| Net Profit Margin | 3.64% |
| Debt/Equity Ratio | 85.8% |
How did OPCH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/21 21:51 |
| End of Day Share Price | 2026/07/21 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Option Care Health, Inc. is covered by 15 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Petusky | Barrington Research Associates, Inc. |
| Joanna Sylvia Gajuk | BofA Global Research |
| Richard Close | Canaccord Genuity |